Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00152984
First received: September 8, 2005
Last updated: October 31, 2013
Last verified: October 2013
  Purpose

The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Asthma
Drug: Tiotropium inhalation capsules
Drug: Placebo inhalation capsules
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • AUC(0-6) FEV1 (Area under the curve of change in FEV1 from baseline to 6 hours post dose) [ Time Frame: after 12 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Forced vital capacity (FVC) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Peak expiratory flow rate (PEFR) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Use of rescue medication [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • AUC0-6hFEV1 [ Time Frame: after first dose on Day 1 and after 4 weeks of treatment ] [ Designated as safety issue: No ]
  • Change in trough FEV1 (i.e. trough response) from baseline. [ Time Frame: after 4 and 12 weeks of treatment ] [ Designated as safety issue: No ]
  • Change in peak FEV1 from baseline (=peak response) after first dose [ Time Frame: after 4 and 12 weeks of treatment ] [ Designated as safety issue: No ]
  • AUC0-6hFVC defined in the same way as for FEV1. [ Time Frame: Day 1, week 4 ] [ Designated as safety issue: No ]
  • Trough FVC defined in the same way as for FEV1. [ Time Frame: Day 1, week 4 ] [ Designated as safety issue: No ]
  • Peak FVC defined in the same way as for FEV1 [ Time Frame: Day 1, week 4 ] [ Designated as safety issue: No ]
  • Weekly average PEFR in the morning (a.m. pre-dose measurement) and in the evening (p.m. measurement). [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Weekly average number of puffs of rescue medication used [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Occurrence of adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in pulse rate and systolic and diastolic blood pressure (seated) measured just before spirometry [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in Physical examination [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 472
Study Start Date: December 2004
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Diagnosis of COPD and diagnosis of asthma before the age of 30
  • Current or ex-smokers with a cigarette smoking history of at least 10 pack-years
  • Treatment with inhaled steroids at least 1 year before study entry
  • FEV1 increase of more than 12% 30 min. after 400 mcg salbutamol or documented reversibility of 12% documented during the past 5 years
  • FEV1 increase of more than 200 mL 30 min. after 400 mcg salbutamol or documented increase of 200 mL after reversibility test within the last 5 years
  • Post bronchodilator FEV1 less than 80% predicted normal (ECCS) at visit 1
  • Post bronchodilator FEV1 less than 70% of FVC at visit 1

Exclusion criteria:

  • Respiratory infection or exacerbation 6 weeks prior to Visit 1 or during run-in period.
  • Significant diseases other than COPD or asthma
  • Myocardial infarction within the last 6 months
  • Unstable or life-threatening cardiac arrhythmia requiring intervention or change in therapy in the last year
  • Hospitalisation for heart failure (NYHA Class III or IV) within the last year
  • History of life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
  • Known active tuberculosis
  • History of thoracotomy with pulmonary resection
  • History of cancer within the last 5 years (excluding treated basal cell carcinoma)
  • Patients requiring oxygen therapy for more than 1 hour per day
  • Patients currently in a pulmonary rehabilitation programme or who have completed such a programme within 4 weeks before Visit 1
  • Known hypersensitivity to anticholinergic drugs or lactose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00152984

  Show 68 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Pharma GmbH & Co. KG
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00152984     History of Changes
Other Study ID Numbers: 205.301
Study First Received: September 8, 2005
Last Updated: October 31, 2013
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment
France: National Consultative Ethics Committee for Health and Life Sciences
Germany: BfArM Bundesinstitut fuer Arzneimittel und Medizinprodukte
South Africa: Medicines Control Council
Denmark: Danish Medicines Agency
Canada: Health Canada
Italy: Ministry of Health
Netherlands: Medical Ethics Review Committee (METC)

Additional relevant MeSH terms:
Asthma
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Disease Attributes
Pathologic Processes
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014